CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) and Aprea Therapeutics (NASDAQ:APRE – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.
Insider and Institutional Ownership
69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
CRISPR Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500.
Profitability
This table compares CRISPR Therapeutics and Aprea Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CRISPR Therapeutics | -3,368.72% | -24.39% | -18.25% |
| Aprea Therapeutics | N/A | -47.60% | -40.97% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for CRISPR Therapeutics and Aprea Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CRISPR Therapeutics | 1 | 7 | 9 | 2 | 2.63 |
| Aprea Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
CRISPR Therapeutics presently has a consensus target price of $65.75, indicating a potential upside of 27.62%. Aprea Therapeutics has a consensus target price of $2.80, indicating a potential upside of 353.37%. Given Aprea Therapeutics’ higher possible upside, analysts clearly believe Aprea Therapeutics is more favorable than CRISPR Therapeutics.
Valuation & Earnings
This table compares CRISPR Therapeutics and Aprea Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CRISPR Therapeutics | $3.51 million | 1,419.22 | -$581.60 million | ($4.76) | -10.82 |
| Aprea Therapeutics | $290,000.00 | 26.81 | -$12.60 million | ($1.08) | -0.57 |
Aprea Therapeutics has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
CRISPR Therapeutics beats Aprea Therapeutics on 9 of the 14 factors compared between the two stocks.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
About Aprea Therapeutics
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
